Skip to main content

Table 1 Relationship between AR expression and different clinicopathological parameters in 111 breast carcinomas.

From: Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors

Patient and tumor characteristics

N

Median (range)

p

N° positive cases (score >0) (%)

p

Total cases

111

69 (0–288)

 

83 (74.8)

 

Age (years)

  

n.s.

 

n.s.

≤ 58

55

68(0–279)

 

44(80)

 

>58

56

76(0–288)

 

39(69.6)

 

Menopausal status

  

n.s.

 

n.s.

Premenopausal

29

92(0–279)

 

25(86.2)

 

Postmenopausal

82

59(2–288)

 

58(70.4)

 

Tumor size

  

n.s.

 

n.s.

T1

50

80(0–288)

 

40(80)

 

T2

61

64(0–279)

 

43(70.5)

 

Nodal status

  

n.s.

 

n.s.

Positive

52

53(0–273)

 

38(73.1)

 

Negative

59

100(0–288)

 

45(76.3)

 

Stage

  

n.s.

 

n.s.

I

32

71(0–273)

 

25 (78.1)

 

II

51

64(0–243)

 

40 (78.4)

 

III

28

83.5(0–288)

 

18 (64.3)

 

Histologic grade

  

n.s.

 

n.s.

Well Dif.

30

66.5(0–273)

 

22(73.3)

 

Mod. Dif.

57

88(0–288)

 

44(77.2)

 

Poorly Dif.

24

40.5(0–267)

 

17(70.8)

 

Estrogen receptor

  

n.s.

 

n.s.

Negative

52

55.5(0–273)

 

34(65.4)

 

Positive

59

80(0–288)

 

49(83.1)

 

Progesterone receptor

  

n.s.

 

n.s.

Negative

59

58(0–279)

 

41(69.5)

 

Positive

52

76(0–288)

 

42(80.8)

 

Desmoplastic reaction

  

n.s.

 

n.s.

No

35

48(0–270)

 

23(65.7)

 

Yes

76

80.5(0–288)

 

60(78.9)

 

Peritumoral inflammation

  

n.s.

 

n.s.

No

65

69.5(0–279)

 

48(75)

 

Yes

46

86(0–288)

 

34(75.6)

 

Tumor advancing edge

  

n.s.

 

n.s.

Expansive

49

50.5(0–270)

 

33(68.8)

 

Infiltrating

62

84.5(0–288)

 

48(80)

 

Vascular invasion

  

n.s.

 

n.s.

No

72

64.5(0–288)

 

52(72.2)

 

Yes

39

81(0–279)

 

31(79.5)